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Abstract
Objective
This study aims to compare the cost-effectiveness of various strategies of myeloid growth
factor prophylaxis for reducing the risk of febrile neutropenia (FN) in patients with non-Hodg-
kin lymphoma in Singapore who are undergoing R-CHOP chemotherapy with curative
intent.
Methods
AMarkov model was created to compare seven prophylaxis strategies: 1) primary prophy-
laxis (PP) with nivestim (biosimilar filgrastim) throughout all cycles of chemotherapy; 2) PP
with nivestim during the first two cycles of chemotherapy; 3) secondary prophylaxis (SP)
with nivestim; 4) PP with pegfilgrastim throughout all cycles of chemotherapy; 5) PP with
pegfilgrastim during the first two cycles of chemotherapy; 6) SP with pegfilgrastim; and 7)
no prophylaxis (NP). The perspective of a hospital was taken and cost-effectiveness was
expressed as the cost per episode of FN avoided over six cycles of chemotherapy. A proba-
bilistic sensitivity analysis was conducted.
Results
Strategies 3, 6, and 7 were dominated in the base case analysis by strategy 5. The costs
associated with strategies 2, 5, 1, and 4 were US$3,813, US$4,056, US$4,545, and US
$5,331, respectively. The incremental cost-effectiveness ratios for strategy 5 vs. strategy 2,
strategy 1 vs. strategy 5, and strategy 4 vs. strategy 1 were US$13,532, US$22,565, and
US$30,452, respectively, per episode of FN avoided. Strategy 2 has the highest probability
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to be cost-effective (ranged from 48% to 60%) when the willingness to pay (WTP) threshold
is lower than US$10,000 per FN episode prevented.
Conclusion
In Singapore, routine PP with granulocyte colony-stimulating factor (nivestim or pegfilgras-
tim) is cost-effective for reducing the risk of FN in patients receiving R-CHOP.
Introduction
Febrile neutropenia (FN) is a major complication of myelosuppressive chemotherapy. Manage-
ment of this complication is often associated with a high economic burden during cancer care
[1]. Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin
lymphoma (NHL). The first-line treatment for DLBCL includes combination chemotherapy
with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP) [2].
The current guidelines suggest that patients who are undergoing R-CHOP chemotherapy are
at intermediate risk (10% to 20%) for FN and it is recommended that the prophylactic use of
granulocyte colony-stimulating factor (G-CSF) should be considered among patients with risk
factors for FN, such as old age, previous chemotherapy or radiotherapy, and poor performance
status [3, 4].
In Singapore, two types of G-CSF are commercially available, filgrastim and pegfilgrastim (a
second-generation filgrastim with a sustained duration of action). Because the patent for fil-
grastim recently expired, a number of biosimilars of filgrastim are currently under evaluation
and development. Nivestim, a biosimilar filgrastim, was recently approved for clinical use in
Singapore. In a Phase 3 clinical trial, the efficacy and safety of nivestim were demonstrated to
be similar to those of filgrastim [5]. Because the price of biosimilar filgrastim (nivestim) has the
potential to be lower than that of its reference product (filgrastim), there is an opportunity for
nivestim to improve the cost-effectiveness of the prophylaxis strategies for FN.
Although several cost-effectiveness analyses of the prophylactic use of G-CSF among lym-
phoma patients who are undergoing CHOP-based chemotherapy have been published in the
past few years [6–9], the results have been varied (Table 1). Recently, one study from the Euro-
pean G5 countries showed that the prophylactic use of biosimilar filgrastim was more cost-effi-
cient for the reduction of FN under all possible prophylaxis strategies evaluated than filgrastim
and pegfilgrastim [10]. However, to the best of our knowledge, publications regarding the cost-
effectiveness of FN prophylaxis with biosimilar G-CSF among lymphoma patients who are
undergoing R-CHOP chemotherapy are limited. Therefore, the primary objective of this study
was to compare the cost-effectiveness of primary and secondary prophylaxis with biosimilar fil-
grastim (nivestim), pegfilgrastim, or no prophylaxis to reduce the risk of FN in patients with
NHL who were undergoing R-CHOP chemotherapy with curative intent, through the perspec-
tive of a Singaporean hospital.
Methods
Model overview
AMarkov model was constructed with TreeAge Pro 2013 (TreeAge Software, Inc, MA) to
compare seven prophylaxis strategies for FN: 1) primary prophylaxis (PP) with nivestim
through all cycles of chemotherapy; 2) PP with nivestim during the first two cycles of chemo-
therapy; 3) secondary prophylaxis (SP) with nivestim; 4) PP with pegfilgrastim through all
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cycles of chemotherapy; 5) PP with pegfilgrastim during the first two cycles of chemotherapy;
6) SP with pegfilgrastim; and 7) no prophylaxis (NP). Primary prophylaxis is defined as the
routine administration of G-CSF with each cycle of chemotherapy, regardless whether a patient
had previously experienced an episode of FN. Secondary prophylaxis is defined as the initation
of G-CSF in subsequent cycles of chemotherapy after a patient experienced a FN episode. For
both SP strategies (strategies 3 and 6) and those that included PP at the first two cycles of che-
motherapy (strategies 2 and 5), secondary G-CSF prophylaxis was initiated and continued dur-
ing the subsequent cycles once the patient experienced an episode of FN.
The model target population was a hypothetical cohort of patients with NHL (mean age, 55
years) with R-CHOP as a curative treatment. The time horizon of this model was 18 weeks,
which was the period of six chemotherapy cycles. The Markov model was used with a cycle
length of 1 week (7 days).
Model structure
This Markov model included five health states: 1) no FN or history of FN; 2) FN with severe
complications; 3) FN without complications; 4) no FN, but a history of FN; and 5) death of FN
(Fig 1). Death of other causes during chemotherapy was not considered.
In this model, all patients began in health state 1 (no FN or history of FN). Health states 2
and 3 were temporary states that individuals had to exit after 1 week. To integrate the memory
of FN history into the Markov model, health state 4 was added. Health state 5 was set as the
absorbing state. The transitions from state 1 to states 2 and 3, and from state 4 to states 2 and 3
only occurred in week 2 of each chemotherapy cycle (Fig 2). The face validity of this model has
Table 1. A rapid review of cost-effectiveness analyses of G-CSF prophylaxis among lymphoma patients undergoing CHOP-based chemotherapy.
Study Hill G et al. [6] Lathia N et al. [7] Chan KK et al. [8] Lyman G et al. [9]
Year 2014 2013 2012 2009
Location United States Canada Canada United States
Perspective Government payer Healthcare systems Government payer Health insurers
Design Decision tree + Markov cohort Markov cohort Markov cohort Decision tree + Markov cohort
Population 66-year-old NHL patients
(modeled)
64-year-old DLBCL patients
(modeled)
Newly diagnosed DLBCL
patients (modeled)
Intermediate / high-grade NHL
(modeled)
Comparators 1) PP with pegﬁlgrastim 2) SP
with pegﬁlgrastim
1) NP 2) PP with 10 days of
ﬁlgrastim 3) PP with
pegﬁlgrastim
1) PP with 10 days of ﬁlgrastim
2) SP with 10 days of
ﬁlgrastim
1) PP with pegﬁlgrastim 2) PP
with 6 days of ﬁlgrastim
Time
horizon
Lifetime 6 cycles of chemotherapy (18
weeks)
8 cycles of chemotherapy Lifetime
Cost Direct medical cost (2012 USD) Direct medical cost (2012 CAD) Direct medical cost (2010 CAD) Direct medical cost (2006 USD)
Outcomes LYS; QALY gained; FN event
avoided
QALY gained QALY gained LYS; QALY gained; FN event
avoided
Main
Results
ICERs for #1 vs. #2 were
$15,000 per FN event
avoided, $33,000 per QALY
gained, and $28,900 per LYS;
PP with pegﬁlgrastim was
cost-effective vs. SP with
pegﬁlgrastim at a WTP
threshold of $50,000 per
QALY
ICERs for #2 vs. #1 and #3 vs.
#2 were CAD $5,796,000 per
QALY and CAD $2,611,000
per QALY, respectively;
Neither PP with pegﬁlgrastim
nor PP with ﬁlgrastim were
cost-effective vs. NP
ICER for #1 vs. #2 was
$700,500 per QALY gained;
PP with ﬁlgrastim was not
cost-effective vs. SP with
ﬁlgrastim at a WTP threshold
of $100,000/QALY
ICERs for strategy #1 vs. #2
were $2,167/FN episode
avoided, $5,532 per LYS,
and $6,190 per QALY
gained; PP with
pegﬁlgrastim was cost-
effective vs. PP with
ﬁlgrastim
NP = no prophylaxis; PP = primary prophylaxis; SP = secondary prophylaxis; pts = patients; USD = US dollars; CAD = Canada dollars; QALY = quality-
adjusted life year; LYS = life year saved; ICER = incremental cost-effectiveness ratio;WTP = willingness-to-pay
doi:10.1371/journal.pone.0148901.t001
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been discussed and confirmed with local experts and clinicians. This study was approved by
the SingHealth Institutional Review Board. Informed consent was waived, and patient records/
information was anonymized and de-identified prior to analysis.
Model inputs
Cost. The cost data on nivestim and pegfilgrastim were obtained from National Cancer
Center Singapore (NCCS). The cost of medication administration was not included because
the patients self-inject G-CSF based on local practice (Table 2).
Although episodes of FN may lead to a dose reduction or a delay in chemotherapy that may
affect the patient’s treatment cost, for this study, the variation on treatment costs was limited
because the simulated cohort of patients were undergoing curative-intent chemotherapy. It
was therefore assumed that the costs of chemotherapy were the same across all arms of the
model, so these costs were not included in our analysis.
The costs of hospitalization for FN among lymphoma patients with and without serious
complications were obtained through an observational study conducted at the NCCS [11]. A
previous study in Singapore reported that more than 95% of cases of FN were managed in an
Fig 1. Structure of Markov state transition model.
doi:10.1371/journal.pone.0148901.g001
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inpatient setting [12]. To simplify the model, all FN events in this study were assumed to
require hospitalization.
All costs were first adjusted to 2013 Singapore dollars by the Singapore consumer price
index (health care component) [13]. The cost data were then converted to US dollars using the
2013 purchasing power parity conversion rate of 1 USD = 0.88 SGD [14], obtained from the
World Bank.
Utilities. Utility estimates were generated from a local study in Singapore [15]. In that
study, there are a total of 67 hospitalized patients with lymphoma who were undergoing che-
motherapy. Twenty-eight out of 67 patients (41.8%) developed FN within the past 7 days from
the interview date, among which 7 patients (25%) experienced severe complications. The Euro-
Qol 5-Dimensions questionnaire (EQ-5D) was administered to each patient, and the average
utility index score was calculated to estimate the utility value for each health state. EQ-5D util-
ity index scores were calculated using a Japanese value set, which offers the closest approxima-
tion to Singapore’s population [16].
Probabilities and efficacy. Table 2 shows the efficacy of pegfilgrastim in the prevention of
FN in patients with NHL estimated with data from a local retrospective study [17]. We
assumed that nivestim had an efficacy equivalent to that of filgrastim [5] and estimated its
Fig 2. Markov trace of the cohort simulation for the first two cycles of chemotherapy.
doi:10.1371/journal.pone.0148901.g002
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efficacy on the basis of a randomized trial in lymphoma patients [18]. Nivestim was assumed
to be given for 7 days per cycle of chemotherapy [17].
The relative risk (RR) of FN with and without a history of FN within each chemotherapy
cycle was based on an observational study that was conducted by the NCCS [17]. The risk of
severe complications in cases of FN was estimated in a study conducted in Singapore [11].
In addition, the risks of the development of FN without PP with G-CSF were obtained from
Lyman et al. [19]. It was assumed that R-CHOP had a risk of FN equivalent to that of the
CHOP regimen [20]. The risks of the development of FN in cycles 2 to 6 were assumed to be
equivalent [19].
The case-fatality rates for FN with and without severe complications in patients with NHL
were based on a prospective observational study [21] from Singapore.
Model analyses
The model outputs included the total costs, the number of FN episodes prevented, and the
quality-adjusted life years (QALYs) gained for each of the seven prophylaxis strategies. The pri-
mary outcome of this economic evaluation was the incremental cost per episode of FN pre-
vented. If a strategy was more costly and did not provide any additional benefit (i.e., both more
costly and less effective), it was considered to be “dominated.”
A probabilistic sensitivity analysis was performed and a beta distribution was used to reflect
the uncertainty in the risk. The cost parameters were assumed to follow a gamma distribution.
A log-normal distribution was used for the RR. The parameters of these distributions were
derived from published literature when available [11, 17–19, 21]. The Monte Carlo simulation
was conducted for 10,000 iterations for each comparison. The cost-effectiveness acceptability
curves were generated on the basis of the results of the probabilistic sensitivity analysis.
Table 2. Model inputs.
Parameters Value Reference PSA distribution
Costs, 2013 USD
Pegﬁlgrastim 6 mg (per injection) 532 USD NCCS N/A
Nivestim 300 μg (7 days of injections) 352 USD NCCS, [17] N/A
Hospitalization cost for FN with complications 22,135 USD NCCS, [11] Gamma (α = 29.23, λ = 0.0013)
Hospitalization cost for FN without complications 9,588 USD NCCS, [11] Gamma (α = 98.72, λ = 0.010)
Utilities
NHL with chemotherapy (without FN) 0.80 NCCS, [15] Beta (α = 92.70, ß = 23.17)
FN without complications 0.77 NCCS, [15] Beta (α = 61.33, ß = 18.42)
FN with severe complications 0.43 NCCS, [15] Beta (α = 4.43, ß = 5.78)
Probabilities and efﬁcacy
Relative risk of FN (versus no G-CSF); pegﬁlgrastim 0.55 [17, 19] Log-normal (mean = -0.60, SD = 0.22)
Relative risk of FN (versus no G-CSF); nivestim 0.62 [18, 19] Log-normal (mean = -0.48, SD = 0.13)
Relative risk of FN; with FN history (versus no FN history) 2.29 NCCS, [17] Log-normal (mean = 0.83, SD = 0.40)
FN risk in cycle 1; no prophylaxis 0.17 [19] Beta (α = 84, ß = 410)
FN risk in cycles 2 to 6; no prophylaxis 0.03 [19] Beta (α = 61, ß = 349)
Risk of severe complications in cases of FN 0.14 NCCS, [11] Beta (α = 13, ß = 83)
FN with complications case fatality rate 0.025 [21] Beta (α = 4, ß = 154)
FN without complications case fatality rate 0.0063 [21] Beta (α = 1, ß = 157)
USD = US dollars; N/A = not available; NCCS = National Cancer Centre Singapore; PSA = Probabilistic sensitivity analysis; G-CSF = granulocyte colony-
stimulating factor; FN = Febrile neutropenia; SD = Standard deviation; NHL = non Hodgkin’s lymphoma
doi:10.1371/journal.pone.0148901.t002
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A scenario analysis was performed. The cost per QALY gained was chosen as the outcome
for each individual prophylactic strategies. In addition, a threshold analysis was conducted, of
which the cost of nivestim was varied downward until the PP with nivestim (all cycles) became
the most cost-effective prophylaxis strategy. A cost-effectiveness threshold of US$100,000 per
QALY gained was employed.
Results
Base-case analysis
Table 3 shows the total and incremental health outcomes and costs associated with all seven
FN management strategies (cost per FN episode prevented as the main outcome). NP, SP with
nivestim, and SP with pegfilgrastim were dominated by PP with pegfilgrastim (cycles 1 and 2).
The costs associated with PP with nivestim (cycles 1 and 2), PP with pegfilgrastim (cycles 1 and
2), PP with nivestim (all cycles), and PP with pegfilgrastim (all cycles) were US$3,813, US
$4,056, US$4,545, and US$5,331, respectively. The number of FN episodes per patient through-
out all six cycles of chemotherapy were 0.25, 0.24, 0.21, and 0.19, respectively.
The incremental cost-effectiveness ratio (ICER) for PP with pegfilgrastim (cycles 1 and 2)
compared with PP with nivestim (cycles 1 and 2) was US$13,532 per episode of FN prevented;
for PP with nivestim (all cycles) compared with PP with pegfilgrastim (cycles 1 and 2), the
ICER was US$22,565 per episode of FN prevented; and for PP with pegfilgrastim (all cycles)
compared with PP with nivestim (all cycles), the ICER was US$30,452 per episode of FN pre-
vented (Table 3).
Probabilistic sensitivity analysis
The cost-effectiveness acceptability curve from the probabilistic sensitivity analysis (Fig 3)
revealed that PP with nivestim (cycles 1 and 2) has the highest probability to be cost-effective
(ranged from 48% to 60%) when the willingness to pay (WTP) threshold is lower than US
$10,000 per FN episode prevented. In contrast, if the WTP threshold is higher than US$20,000
per FN episode prevented, PP with G-CSF (nivestim or pegfilgrastim) for all cycles would
become the prophylaxis strategy with the highest probability to be cost-effective.
Table 3. Results of the costs and effectiveness of the prophylaxis strategies (cost per FN episode prevented).
Strategy Cost, 2013
USD
Episode of FN per
patient @
Incremental cost, 2013
USD
Incremental FN episode
prevented
ICER, 2013
USD
PP with nivestim (cycles 1 &
2)
3,813 0.25 reference reference reference
PP with pegﬁlgrastim (cycles
1 & 2)
4,056 0.24 243 0.02 13,532
PP with nivestim (all cycles) 4,545 0.21 489 0.02 22,565
PP with pegﬁlgrastim (all
cycles)
5,331 0.19 786 0.03 30,452
No prophylaxis * 4,101 0.36 - - - - Dominated
SP with nivestim * 4,162 0.33 - - - - Dominated
SP with pegﬁlgrastim * 4,297 0.33 - - - - Dominated
@ Throughout all six cycles of chemotherapy
* Dominated by PP with pegﬁlgrastim (cycles 1 and 2)
PP = Primary prophylaxis; SP = Secondary prophylaxis; FN = Febrile neutropenia; USD = US dollars; ICER = Incremental cost-effectiveness ratio
doi:10.1371/journal.pone.0148901.t003
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Scenario analysis
Table 4 shows the total and incremental health outcomes and costs associated with all seven
FN management strategies (cost per QALY gained as the main outcome). NP, SP with nives-
tim, and SP with pegfilgrastim were dominated by PP with pegfilgrastim (cycles 1 and 2). PP
with nivestim (all cycles) was extended dominated by the mixed strategy of PP with pegfilgras-
tim (cycles 1 and 2) and PP with pegfilgrastim (all cycles). When the cost of nivestim (7 days of
injections) was lower than US$137, PP with nivestim throughout all cycles of chemotherapy
would become cost-effective at a threshold of US$100,000 per QALY gained.
Discussion
In our study, we found that NP, SP with nivestim, and SP with pegfilgrastim were dominated
by PP with pegfilgrastim (cycles 1 and 2) in the base case analysis. This advocates for a routine
PP strategy to prevent FN among all patients with NHL who undergo R-CHOP chemotherapy.
We recently published a study of the economic burden of FN among patients in Singapore
with solid tumors and lymphoma. The inpatient management cost of FN was US$4193 per epi-
sode, and the management cost of FN in lymphoma cases (US$6560) was the highest among
the cancer types [11]. Hence, this emphasizes the importance to routinely PP patients with
G-CSF (nivestim or pegfilgrastim) who are undergoing R-CHOP in Singapore in order to
Fig 3. Cost-effective acceptability curve (cost per FN episode prevented).
doi:10.1371/journal.pone.0148901.g003
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prevent the occurrence of FN, as this strategy is cost effective and it reduces patients’ risks of
FN risks for hospitalization and infectious-related complications.
Considering the short time horizon (18 weeks) in our proposed model, it is not suitable to
use QALYs as the primary outcome for this study, because the benefit of reducing the FN-
related mortality rate using G-CSF cannot be fully captured within a relative short time horizon
(during the chemotherapy cycles). Therefore, we have chosen the ICER involving natural
health units (episodes of FN prevented) as the main outcome for this study. However, we have
also conducted our analysis using the cost per QALY gained approach, in order to ensure our
study findings are comparable to other cost-effectiveness studies [6–9]. It should be noticed
that when the cost per QALY gained approach was used, multiple strategies (NP, SP with
nivestim, and SP with pegfilgrastim) are still dominated by PP with pegfilgrastim (cycles 1 and
2) in the base case analysis. This demonstrates robustness of our main finding that a routine
PP strategy to prevent FN should be advocated among all patients with NHL receiving
R-CHOP chemotherapy.
A recent US study evaluated the cost-effectiveness of G-CSF prophylaxis among patients
with NHL who were undergoing CHOP-based chemotherapy [6]. In that study, a time horizon
of life was used and the cost-effectiveness was assessed by the ICER involving QALYs. PP with
G-CSF was found to be cost-effective when compared with SP with G-CSF at a WTP threshold
of US$50,000 per QALY. This is consistent with the findings in our study. A Canadian study
[7] assessed the cost-effectiveness of PP with G-CSF among patients with DLBCL who under-
went R-CHOP during six cycles of chemotherapy. It was reported that PP with G-CSF was not
cost-effective when compared with NP at a WTP threshold of US$50,000 per QALY. The main
reason why this study presents different results from the current study [6] could be due to the
relatively short time horizon they have chosen and they have included the NP strategy as the
reference (assuming NP strategy is the standard care in their settings). We believe that the
assessment of the cost-effectiveness of G-CSF prophylaxis within a shorter time horizon (dur-
ing the chemotherapy cycles) is more appropriate because FN is an acute illness and there is lit-
tle evidence to support the long-term benefits of G-CSF prophylaxis. However, it was identified
in our study that the NP strategy was dominated by the PP with G-CSF (nivestim or pegfilgras-
tim) for the first two cycles of chemotherapy. To our knowledge, this is the first study that has
evaluated the value of PP with G-CSF during the first two cycles of chemotherapy among lym-
phoma patients. One previous study [22] concluded that G-CSF prophylaxis for all cycles of
Table 4. Results of the costs and effectiveness of the prophylaxis strategies (cost per QALY gained).
Strategy Cost, 2013 USD QALYs @ Incremental cost, 2013 USD Incremental QALYs gained ICER, 2013 USD
PP with nivestim (cycles 1 & 2) 3,813 0.2754 reference reference reference
PP with pegﬁlgrastim (cycles 1 & 2) 4,056 0.2755 243 0.0001 4,058,623
PP with pegﬁlgrastim (all cycles) 5,331 0.2756 1,275 0.0001 11,928,289
PP with nivestim (all cycles) ^ 4,545 0.2755 - - - - Dominated
No prophylaxis * 4,101 0.2751 - - - - Dominated
SP with nivestim * 4,162 0.2733 - - - - Dominated
SP with pegﬁlgrastim * 4,297 0.2752 - - - - Dominated
@ Throughout all six cycles of chemotherapy
* Dominated by PP with pegﬁlgrastim (cycles 1 and 2)
^ Extended dominated by a mixed strategy of PP with pegﬁlgrastim (cycle 1&2) and PP with pegﬁlgrastim (all cycles)
PP = Primary prophylaxis; SP = Secondary prophylaxis; FN = Febrile neutropenia; QALYs = quality-adjusted life years; USD = US dollars; ICER =
Incremental cost-effectiveness ratio
doi:10.1371/journal.pone.0148901.t004
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chemotherapy is more effective in patients with breast cancer, but associated with higher cost,
when compared to the administration of prophylaxis solely for the first two cycles of chemo-
therapy. However, the cost-effectiveness of PP with G-CSF limited to the first two cycles has
not been determined. The results in our study demonstrated that this strategy is cost-effective
when compared to the PP with G-CSF for all cycles as this strategy generates a sizable cost-sav-
ing with a slight loss on the health benefits that may not be clinically significant. However, fur-
ther studies are required to refine and optimize a dosing regimen that requires less G-CSF.
We identified that when the cost of nivestim (7 days of injections) was lower than US$137,
PP with nivestim throughout all cycles of chemotherapy was cost-effective and should be rou-
tinely recommended as PP. This result implies that as the cost of biosimilar G-CSF continues
to decrease, the use of G-CSF will be encouraged in such a way that patients’ access to the treat-
ment will increase. It was recently reported that the availability of a lower-cost biosimilar
G-CSF was associated with a 10% to 20% increase in the use of G-CSF in Europe [23]. This had
a major effect on clinical practice, as many clinicians are moving away from SP to more routine
PP [24]. However, the adoption of a biosimilar in clinical practice should not be driven only by
monetary concerns but also by its safety and efficacy [24]. Two prospective observational stud-
ies of nivestim (biosimilar filgrastim) are currently underway [25]. It is expected that the long-
term safety and efficacy data provided by these two studies will promote our understanding of
the performance of nivestim in clinical practice. An additional cost-effectiveness analysis may
be necessary in the future to compare the cost-effectiveness of other biosimilar filgrastim with
its reference product (filgrastim).
Our study has several limitations. First, the efficacy of nivestim was assumed to be equiva-
lent to that of filgrastim. Although it is safe for us to assume that their efficacies are similar, this
uncertainty may have affected our results. Second, we presented all-cause mortality in our
model, as we were unable to segregate the mortality of other causes during chemotherapy. This
could potentially lead to an overestimation on both costs and effectiveness. However, given the
short time horizon in this model (18 weeks) and most mortality during this period are related
to FN, exclusion of this health state should not lead to significant impact.
In conclusion, routine PP with G-CSF (nivestim or pegfilgrastim) is cost-effective in Singa-
pore for reducing the risk of FN in patients receiving R-CHOP than other strategies including
secondary prophylaxis or not offering prophylaxis.
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